Registered title, quoted from ClinicalTrials.gov
Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
An open trial on pancreatic cancer, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06156267, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Patients with radiographically resectable primary pancreatic tumors with histopathology or cytology confirmed resected ductal pancreatic adenocarcinoma (PDAC) with macroscopic complete resection (R0 and R1).
Inclusion criterion 2
Pancreatic cancer surgical staging per AJCC 8th edition staging: T 1-3, N0-2, M0.
Inclusion criterion 3
Have any active autoimmune disease, or have a history of autoimmune disease and have received systemic therapy in the past 2 years.
Exclusion criterion 4
Active tuberculosis or a history of active tuberculosis infection within 28 days prior to initiation of study treatment.
Exclusion criterion 5
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Inclusion criterion 5
Prior malignancy within 5 years prior to study entry.
Exclusion criterion 8
Active hepatitis B (HBV-DNA≥1000IU/ml), hepatitis C (hepatitis C antibody positive, and HCV-RNA higher than the lower limit of assay).
Exclusion criterion 13
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06156267, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntarily signed the informed consent form and complied with protocols requirements.
- Patients with radiographically resectable primary pancreatic tumors with histopathology or cytology confirmed resected ductal pancreatic adenocarcinoma (PDAC) with macroscopic complete resection (R0 and R1).
- Pancreatic cancer surgical staging per AJCC 8th edition staging: T 1-3, N0-2, M0.
- Tumour specimen availability.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Life expectancy ≥ 6 months.
- Surgical complications have recovered, or complications lower than Clavien-Dindo complication grade 3.
- Adequate marrow and organ function.
- Patients with fertility are willing to use an adequate method of contraception.
Exclusion Criteria:
- Prior anti-PDAC therapy (e.g., chemotherapy, radiotherapy, targeted therapy, immunotherapy and therapeutic tumor vaccines) prior to initiation of study treatment.
- Unsuitable for immunotherapy assessed by the investigator.
- Plan to receive a live-attenuated vaccine within 28 days prior to initiation of study treatment or during the study treatment or within 90 days after the end of study treatment.
- Have any active autoimmune disease, or have a history of autoimmune disease and have received systemic therapy in the past 2 years.
- Active tuberculosis or a history of active tuberculosis infection within 28 days prior to initiation of study treatment.
- Known or highly suspected history of interstitial pneumonia.
- Allergic to research drug ingredients, or have a history of severe allergic reactions to other vaccines.
- Prior malignancy within 5 years prior to study entry.
- Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
- Known splenectomy history.
- Concurrent severe infection within 28 days prior to initiation of study treatment.
- Congenital or acquired immune deficiency.
- Active hepatitis B (HBV-DNA≥1000IU/ml), hepatitis C (hepatitis C antibody positive, and HCV-RNA higher than the lower limit of assay).
- Uncontrolled or severe cardiovascular disease.
- Other situations that are not suitable for inclusion in this study judged by investigator.
Quoted from ClinicalTrials.gov, NCT06156267, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06156267, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.